DBV Technologies S.A. (EPA:DBV)

Market Cap	620.83M +187.7%
Revenue (ttm)	4.41M +33.1%
Net Income	-154.01M
EPS	-0.53
Shares Out	295.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,691,415
Open	2.250
Previous Close	2.264
Day's Range	2.070 - 2.274
52-Week Range	1.506 - 4.500
Beta	-0.24
Analysts	Buy
Price Target	3.64 (+73.5%)
Earnings Date	Oct 28, 2026

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 170
• Stock Exchange: Euronext Paris
• Ticker Symbol: DBV

Financial Performance

In 2025, DBV Technologies's revenue was $5.64 million, an increase of 35.77% compared to the previous year's $4.15 million. Losses were -$146.95 million, 29.0% more than in 2024.

Financial numbers in USD

Analyst Summary

According to 4 analysts, the average rating for DBV stock is "Buy." The 12-month stock price target is €3.64, which is an increase of 73.50% from the latest price.

Price Target

€3.64

(73.50% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error